[Bevacizumab. Progress in cancer therapy by antiangiogenesis].

  title={[Bevacizumab. Progress in cancer therapy by antiangiogenesis].},
  author={Irene Kr{\"a}mer and H G Lipp},
  journal={Medizinische Monatsschrift fur Pharmazeuten},
  volume={29 7},
  pages={249-54; quiz 255-6}
Bevacizumab represents the first humanized monoclonal antibody with antiangiogenic properties which has been introduced in clinical oncology. The VEGF antagonist is used for the treatment of advanced colorectal cancer based on significant survivial benefits. Besides hypertension, proteinuria, wound healing disorders, bleeding and thromboembolic events… CONTINUE READING